Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ERBB2-Negative Early Breast Cancer
Sign Up to like & getrecommendations! Published in 2025 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2025.3700
Abstract: This exploratory 4-year analysis of the NATALEE randomized clinical trial evaluates efficacy and safety of adjuvant ribociclib beyond the planned 3-year treatment period. read more here.
Keywords: therapy hormone; hormone receptor; ribociclib plus; endocrine therapy ... See more keywords
CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan
Sign Up to like & getrecommendations! Published in 2024 at "Future Oncology"
DOI: 10.1080/14796694.2024.2441649
Abstract: ABSTRACT Background Though efforts have been made toward standardizing access to quality cancer care in Japan, there are still geographical and institutional disparities in the level of cancer care availability. We investigated the utilization of… read more here.
Keywords: cancer; cdk4; advanced breast; endocrine therapy ... See more keywords
Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Science"
DOI: 10.1111/cas.14554
Abstract: The ongoing, Phase Ib MONALEESASIA study is evaluating the efficacy and safety of ribociclib plus endocrine therapy in Asian patients with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer. Eligible patients from… read more here.
Keywords: endocrine therapy; phase; japanese patients; plus endocrine ... See more keywords